C4 Therapeutics, Inc.
No SEC Form 4 filings for $CCCC in the last 30 days.
See all $CCCC insider activity →C4 Therapeutics, Inc. (CCCC) filed an SEC Form 8-K — Regulation FD Disclosure. C4 Therapeutics Presents New Biomarker Data from the Cemsidomide Phase 1 Trial with Dexamethasone and Phase 1b Trial with Elranatamab (ELREXFIO®) in Relapsed/Refractory Multiple Myeloma at the 23rd International Myeloma Society (IMS) Annual Meeting Immunomodulatory Effects of Cem
C4 Therapeutics shares rose 3.8% in morning trading after the company reported Q2 2026 results. Net loss per share was $0.18, better than the $0.21 consensus, but revenue was $6.64M versus $8.2M expected, citing research wind-downs under Merck and Merck KGaA collaborations. Management said cemsidomide Phase 2 MOMENTUM and Phase 1b combo studies remain on track for 2027 data.
C4 Therapeutics, Inc. (CCCC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 C4 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights Cemsidomide’s Ongoing Phase 2 MOMENTUM Trial and Phase 1b Trial in Combination With Elranatamab Remain on Track to Deliver Clinical Data Readouts in 2027 Phase 1 Data Present
Over the past 7 days, AlphAI's AI scored 1 news story mentioning CCCC (C4 Therapeutics, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent CCCC coverage spans financial news, corporate actions and earnings.
Positive early‑stage data may lift sentiment and support near‑term price upside.
The stock move is driven by an EPS beat plus reiterated clinical readout timing, partially offset by a revenue miss tied to collaboration research wind-downs.
The filing combines quarterly financials with near-term clinical and funding catalysts, supporting a higher probability of 2027 milestone delivery.
Routine shareholder-meeting outcomes; only modest potential impact via approval of the evergreen provision amendment affecting future share issuance.
The company reported better-than-expected revenue and a smaller statutory loss, leading to increased analyst price targets. Despite revenue forecast cuts, positive earnings and analyst optimism suggest potential near-term upside.
AlphAI scores every news story that mentions CCCC with an AI model for sentiment and relevance, and aggregates insider trades from C4 Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
C4 Therapeutics, Inc. (CCCC) filed an SEC Form 8-K — Regulation FD Disclosure. C4 Therapeutics Presents New Biomarker Data from the Cemsidomide Phase 1 Trial with Dexamethasone and Phase 1b Trial with Elranatamab (ELREXFIO®) in Relapsed/Refractory Multiple Myeloma at the 23rd International Myeloma Society (IMS) Annual Meeting Immunomodulatory Effects of Cem
2 min readC4 Therapeutics shares rose 3.8% in morning trading after the company reported Q2 2026 results. Net loss per share was $0.18, better than the $0.21 consensus, but revenue was $6.64M versus $8.2M expected, citing research wind-downs under Merck and Merck KGaA collaborations. Management said cemsidomide Phase 2 MOMENTUM and Phase 1b combo studies remain on track for 2027 data.
4 min readC4 Therapeutics, Inc. (CCCC) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 C4 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights Cemsidomide’s Ongoing Phase 2 MOMENTUM Trial and Phase 1b Trial in Combination With Elranatamab Remain on Track to Deliver Clinical Data Readouts in 2027 Phase 1 Data Present
7 min readC4 Therapeutics, Inc. (CCCC) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. cccc-20260624 0001662579 false 0001662579 2026-06-24 2026-06-24 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _________________________________________________________________ FORM 8-K _________________________________________________________________ CUR
2 min readC4 Therapeutics (NASDAQ:CCCC) surpassed analyst revenue expectations but reported a statutory loss smaller than predicted. Despite analysts cutting 2026 revenue forecasts, they also reduced estimated losses, leading to a 17% increase in the consensus price target to US$11.57. However, the wide range in analyst estimates suggests difficulty in accurately valuing the company, especially given projected revenue declines greater than the broader industry.
3 min readC4 Therapeutics has initiated a Phase 1b clinical trial combining cemsidomide with elranatamab and dexamethasone for relapsed or refractory multiple myeloma, targeting readout by mid-2027. The trial aims to assess optimal dosing and safety, with secondary measures including overall response and duration of response. This strategic move positions cemsidomide for combination therapies to achieve deeper and more durable responses in myeloma treatment.
3 min readC4 Therapeutics, Inc. has announced its financial results for the fourth quarter and full year 2025. The company also provided an update on recent business developments. Stakeholders are encouraged to consult the official press release for a detailed review of the figures and insights.
2 min readC4 Therapeutics reported its Q4 and full-year 2025 financial results, showing revenues of $35.9 million and a net loss of $105.0 million. The company ended 2025 with $297.1 million in cash, which is expected to fund operations until the end of 2028. Key clinical updates include the advancement of cemsidomide into a Phase 2 trial for multiple myeloma and a planned Phase 1b combination study.
2 min readC4 Therapeutics (C4T) announced its financial results for the fourth quarter and full year 2025, highlighting significant progress in advancing cemsidomide into later-stage clinical trials for multiple myeloma, including the initiation of the Phase 2 MOMENTUM trial. The company also reported a strong financial position with $297.1 million in cash, cash equivalents, and marketable securities, extending its operational runway to the end of 2028. Additionally, C4T achieved a milestone payment from Biogen for a BTK degrader entering clinical development, underscoring its successful collaboration strategy.
3 min readThis article summarizes a bullish thesis on C4 Therapeutics, Inc. (CCCC) from Ridire Research, highlighting the company's leading position in targeted protein degradation (TPD) for precision oncology. C4's proprietary E3 ligase platform, strategic focus on orphan oncology indications, and capital discipline are presented as key strengths. The report notes upcoming catalysts like efficacy data and milestone payments, positioning CCCC for sustained value creation despite class-wide safety and competition risks.
5 min read
